Clinical Trial Update: Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial update on safety, tolerability, and biomarker effects of PBI-4050 in subjects with Alström Syndrome, a condition involving inflammation and fibros…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alström Syndrome
• Diabetes
• Inflammation and Fibrosis

Drugs mentioned

• PBI-4050

Snippet

Sponsor: Liminal BioSciences Ltd. | Conditions: Inflammation and Fibrosis, Diabetes | Phase 2 | Status: COMPLETED